View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 4, 2022

UroGen commences Phase III non-muscle invasive bladder cancer trial

The Phase III trial is anticipated to enrol nearly 220 subjects across 90 centres.

UroGen Pharma has commenced the Phase III ENVISION clinical trial of its investigational treatment UGN-102 (mitomycin) for intravesical solution, to treat low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) patients.

The first commercial product of the company, UGN-102 for intravesical solution is intended to remove tumours without surgical procedures.

The multinational, single-arm, multicentre trial will analyse UGN-102’s efficacy and safety as primary chemoablative treatment in individuals with low-grade, intermediate-risk NMIBC. 

It is anticipated to enrol nearly 220 subjects across 90 trial centres. 

In the trial, subjects will be given six once-a-week intravesical instillations of UGN-102. 

The complete response rate at three months post initial instillation is the planned primary endpoint of the trial.

Durability over time in subjects who attain complete response at the three-month analysis will be a secondary endpoint.

As per the talks with the US Food and Drug Administration (FDA) and enrolment expected by the end of this year, the company expects to file a New Drug Application for UGN-102 in 2024 on obtaining positive results.

The trial design of ENVISION is identical to the Phase IIb OPTIMA II trial, which will have subjects with the same clinical features, therapy regimen, analysis and qualitative follow up.

However, both trials will have separate endpoints.

UroGen chief medical officer Mark Schoenberg said: “We have achieved consistent results with similar study designs in the past and believe that it increases our probability for technical and regulatory success for UGN-102 in patients with low-grade, intermediate-risk NMIBC. 

“We look forward to reporting data from ATLAS and acquiring new scientific evidence from ENVISION as we continue to explore the potential benefits of chemoablation in other types of bladder cancer, including high-grade disease and other specialty cancers.”

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy